Verastem Oncology

Verastem Oncology Reprioritizes R&D, Shifting Focus from Avutometinib and Defactinib Combo in Pancreatic Cancer

Verastem Oncology is reprioritizing R&D efforts away from its approved avutometinib plus defactinib combo for first-line metastatic pancreatic cancer, following "good-but-not-great" updated data. This strategic shift signals potential commercial de-emphasis for the combo, impacting long-term supply chain investment, market penetration, and competitive dynamics in the oncology sector. Procurement and business development teams should assess Verastem's future commitment to these molecules.